RT Journal Article
T1 DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
A1 Hidalgo-Tenorio, Carmen
A1 Pasquau, Juan
A1 Vinuesa, David
A1 Ferra, Sergio
A1 Terrón, Alberto
A1 SanJoaquín, Isabel
A1 Payeras, Antoni
A1 Martínez, Onofre Juan
A1 López-Ruz, Miguel Ángel
A1 Omar, Mohamed
A1 de la Torre-Lima, Javier
A1 López-Lirola, Ana
A1 Palomares, Jesús
A1 Blanco, José Ramón
A1 Montero, Marta
A1 García-Vallecillos, Coral
K1 DOLAVI
K1 HIV
K1 dolutegravir
K1 lamivudine
K1 real-world data
AB Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a test-and-treat strategy. Background: Our objectives were to determine the real-life effectiveness and safety of DT with dolutegravir (50 mg/QD) plus lamivudine (300 mg/QD) in a multiple-tablet regimen (MTR) in naïve PLHIV followed up for 48 weeks and to evaluate the compliance and satisfaction of patients. Material and methods: An open, single-arm, multicenter, non-randomized clinical trial from May 2019 through September 2020 with a 48-week follow-up. Results: The study included 88 PLHIV patients (87.5% male) with a mean age of 35.9 years; 76.1% were MSM patients. The mean baseline CD4 was 516.4 cells/uL, with a viral load (VL) of 4.49 log10, and 11.4% were in the AIDS stage. DT started within 7 days of first specialist consultation in all patients and the same day in 84.1%; 3.4% had baseline resistance mutations (K103N, V106I + E138A, and V108I); 12.5% were lost to follow-up. At week 48, 86.3% had VL
YR 2022
FD 2022-03-04
LK http://hdl.handle.net/10668/21599
UL http://hdl.handle.net/10668/21599
LA en
DS RISalud
RD Apr 10, 2025